Top

Neuroradiology

Published in:

01-06-2009 | Diagnostic Neuroradiology

Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?

Authors: Christina Mueller-Mang, Thomas Mang, Agnes Pirker, Katharina Klein, Christine Prchla, Daniela Prayer

Published in: Neuroradiology | Issue 6/2009

Abstract

Introduction

Posterior reversible encephalopathy syndrome (PRES) is a clinico-neuroradiological entity, characterized by typical neurological deficits, distinctive magnetic resonance imaging (MRI) features, and a usually benign clinical course. Although frequently seen in association with hypertensive conditions, many other predisposing factors, notably cytotoxic and immunosuppressant drugs have been associated with PRES. The aim of this study was to determine differences in the MR appearance of PRES according to various risk factors.

Methods

Thirty consecutive patients with clinical and MRI findings consistent with PRES were included. We identified 24 patients with hypertension-related conditions, including 14 patients with preeclampsia–eclampsia, and six patients without hypertension, in whom PRES was associated with exposition to neurotoxic substances. Lesion distribution, extent of disease, and number of affected brain regions were compared between patients with PRES with and without hypertension, and patients with PRES with and without preeclampsia–eclampsia, respectively.

Results

No statistically significant differences in distribution of lesions and extent of disease were observed between patients with PRES with or without hypertension, and patients with or without preeclampsia–eclampsia, respectively. The number of affected brain regions was significantly higher in patients with preeclampsia–eclampsia (p = 0.046), and the basal ganglia region was more frequently involved in these patients (p = 0.066).

Conclusion

Apart from a significant higher number of involved brain regions and a tendency for basal ganglia involvement in patients with PRES associated with preeclampsia–eclampsia, the MRI appearance of patients with PRES does not seem to be influenced by predisposing risk factors.

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500. doi:10.1056/NEJM199602223340803 PubMedCrossRef

McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, Teksam M (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189:904–912. doi:10.2214/AJR.07.2024 PubMedCrossRef

Covarrubias DJ, Luetmer PH, Campeau NG (2002) Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 23:1038–1048PubMed

Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28:1320–1327. doi:10.3174/ajnr.A0549 PubMedCrossRef

Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J (2006) Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 27:2179–2190PubMed

Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G (1998) Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 19:415–417PubMed

Russell MT, Nassif AS, Cacayorin ED, Awwad E, Perman W, Dunphy F (2001) Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 19:129–132. doi:10.1016/S0730-725X(01)00217-X PubMedCrossRef

Kastrup O, Maschke M, Wanke I, Diener HC (2002) Posterior reversible encephalopathy syndrome due to severe hypercalcemia. J Neurol 249:1563–1566. doi:10.1007/s00415-002-0895-x PubMedCrossRef

Ito Y, Niwa H, Iida T, Nagamatsu M, Yasuda T, Yanagi T, Sobue G (1997) Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction. Neurology 49:1174–1175PubMed

10.

Strandgaard S, Paulson OB (1984) Cerebral autoregulation. Stroke 15:413–416PubMed

11.

Tamaki K, Sadoshima S, Baumbach GL, Iadecola C, Reis DJ, Heistad DD (1984) Evidence that disruption of the blood–brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension 6:I75–I81PubMed

12.

Mukherjee P, McKinstry RC (2001) Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology 219:756–765PubMed

13.

Rodgers GM, Taylor RN, Roberts JM (1988) Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 159:908–914PubMed

14.

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescent (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576. doi:10.1542/peds.114.2.S2.555 CrossRef

15.

Port JD, Beauchamp NJ Jr (1998) Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics 18:353–367PubMed

16.

Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzalez RG, Koroshetz WJ (1998) Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 51:1369–1376PubMed

17.

Jansen O, Krieger D, Krieger S, Sartor K (1996) Cortical hyperintensity on proton density-weighted images: an MR sign of cyclosporine-related encephalopathy. AJNR Am J Neuroradiol 17:337–344PubMed

18.

Rangi PS, Partridge WJ, Newlands ES, Waldman AD (2005) Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology 47:586–590. doi:10.1007/s00234-005-1376-6 PubMedCrossRef

19.

Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R, Remuzzi G (1992) The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54:775–780. doi:10.1097/00007890-199211000-00002 PubMedCrossRef

20.

Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G (1986) Cyclosporin-induced endothelial cell injury. Lab Invest 55:455–462PubMed

21.

Kochi S, Takanaga H, Matsuo H, Naito M, Tsuruo T, Sawada Y (1999) Effect of cyclosporin A or tacrolimus on the function of blood–brain barrier cells. Eur J Pharmacol 372:287–295. doi:10.1016/S0014-2999(99)00247-2 PubMedCrossRef

22.

Kochi S, Takanaga H, Matsuo H, Ohtani H, Naito M, Tsuruo T, Sawada Y (2000) Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus. Life Sci 66:2255–2260. doi:10.1016/S0024-3205(00)00554-3 PubMedCrossRef

23.

Marsen TA, Weber F, Egink G, Suckau G, Baldamus CA (1999) Cyclosporin A induces prepro endothelin-1 gene transcription in human endothelial cells. Eur J Pharmacol 379:97–106. doi:10.1016/S0014-2999(99)00447-1 PubMedCrossRef

24.

Truwit CL, Denaro CP, Lake JR, DeMarco T (1991) MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol 12:651–659PubMed

25.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042–1049. doi:10.1002/cncr.22921 PubMedCrossRef

26.

Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29:1043–1049. doi:10.3174/ajnr.A0929 PubMedCrossRef

27.

Horbinski C, Bartynski WS, Carson-Walter E, Hamilton RL, Tan HP, Cheng S (2009) Reversible Encephalopathy after Cardiac Transplantation: Histologic Evidence of Endothelial Activation, T-cell Specific Trafficking, and Vascular Endothelial Growth Factor Expression. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A1311

28.

Schoch HJ, Fischer S, Marti HH (2002) Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125:2549–2557. doi:10.1093/brain/awf257 PubMedCrossRef

29.

Bartynski WS, Boardman JF (2008) Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 29:447–455. doi:10.3174/ajnr.A0839 PubMedCrossRef

30.

Brubaker LM, Smith JK, Lee YZ, Lin W, Castillo M (2005) Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging. AJNR Am J Neuroradiol 26:825–830PubMed

31.

Sundgren PC, Edvardsson B, Holtas S (2002) Serial investigation of perfusion disturbances and vasogenic oedema in hypertensive encephalopathy by diffusion and perfusion weighted imaging. Neuroradiology 44:299–304. doi:10.1007/s00234-001-0721-7 PubMedCrossRef

32.

Demirtas O, Gelal F, Vidinli BD, Demirtas LO, Uluc E, Baloglu A (2005) Cranial MR imaging with clinical correlation in preeclampsia and eclampsia. Diagn Interv Radiol 11:189–194PubMed

33.

Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, Bravo SM, Klufas RA, Chai RY, Repke JT (2000) Preeclampsia–eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 217:371–376PubMed

34.

Watanabe Y, Mitomo M, Tokuda Y, Yoshida K, Choi S, Hosoki T, Ban C (2002) Eclamptic encephalopathy: MRI, including diffusion-weighted images. Neuroradiology 44:981–985. doi:10.1007/s00234-002-0867-y PubMedCrossRef

35.

Servillo G, Striano P, Striano S, Tortora F, Boccella P, De Robertis E, Rossano F, Briganti F, Tufano R (2003) Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients. Intensive Care Med 29:2323–2326. doi:10.1007/s00134-003-1901-1 PubMedCrossRef

36.

Rappaport VJ, Hirata G, Yap HK, Jordan SC (1990) Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 162:138–146PubMed

37.

Feekes JA, Cassell MD (2006) The vascular supply of the functional compartments of the human striatum. Brain 129:2189–2201. doi:10.1093/brain/awl158 PubMedCrossRef

Title: Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?
Authors: Christina Mueller-Mang
Thomas Mang
Agnes Pirker
Katharina Klein
Christine Prchla
Daniela Prayer
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Neuroradiology / Issue 6/2009
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-009-0504-0

At a glance: The STEP trials

Springer Medicine

Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2009

Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study

Pial vasodilation and moderate hyperaemia following carotid endarterectomy: new MRI diagnostic signs in hyperperfusion/reperfusion syndrome?

Horizontal stent-assisted coil embolisation of wide-necked intracranial aneurysms with the Enterprise stent—a case series with early angiographic follow-up

Orbital and anterior visual pathway infection and inflammation

UEMS Division of Neuroradiology—a new development for European neuroradiology

Stenting is improving and stabilizing anatomical results of coiled intracranial aneurysms